Revance The — Company Overview, News & Financial Data
Revance is a biotechnology firm developing innovative neuromodulators for aesthetic and therapeutic conditions.
Revance The
About
Revance (NASDAQ:RVNC) is a biotechnology firm focused on the development, manufacturing, and commercialization of innovative neuromodulators and therapeutics for treating a variety of aesthetic and therapeutic conditions. The company is known for its dedication to advancing the science of movement and expression through research in the neuromodulator space. Revance's portfolio includes treatments aimed at conditions such as cervical dystonia and aesthetic enhancements. A keystone project is the development of a next-generation neuromodulator product, designed to offer longer-lasting results in the treatment of dynamic facial lines and medical conditions characterized by muscle spasticity. Revance's objective is to revolutionize the neuromodulator sector by providing superior solutions that improve patient outcomes and enhance quality of life.
Snapshot
Operations
Products and/or services of Revance The
- DaxibotulinumtoxinA (DAXI) for injection, a neuromodulator aimed at aesthetic and therapeutic uses, delivering longer-lasting results in wrinkle reduction.
- RHA Collection of dermal fillers designed for dynamic wrinkles and folds, offering a more natural look and feel.
- The HintMD platform, a financial technology solution providing payment and subscription models for aesthetic practices to enhance patient engagement and loyalty.
- OPUL, a skincare line leveraging patented technology for aesthetic enhancement and skin health maintenance.
- Revance Therapeutics' research on therapeutics, focusing on innovations in neuromodulator and biologic therapies for various medical conditions.
- Partnerships and collaborations aimed at expanding their portfolio and enhancing delivery systems for neuromodulators and other aesthetic treatments.
Revance The executive team
- Mr. Mark J. FoleyCEO & Director
- Mr. Tobin C. SchilkeCFO & Principal Accounting Officer
- Mr. Dwight O. Moxie J.D.Chief Legal Officer & General Counsel
- Ms. Amie KrauseChief People Officer
- Dr. Conor GallagherHead of Medical Affairs & Aesthetics
- Dr. David A. Hollander M.B.A., M.D.Chief Medical Officer of Global Therapeutics Franchise Lead
- Ms. Erica JordanChief Commercial Officer
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift